GlaxoSmithKline (GSK) is to acquire a biopharmaceutical company Corixa for approximately US$300 M in cash at a price of US$4.40 for each share of Corixa common stock. GSK will also assume Corixa's outstanding convertible debt notes of about US$100 M.